Kornbluth J, Flomenberg N, and Dupont B: Cell surface phenotype of a cloned line of human natural killer cells. J. Immunol. 129:2831-2837, 1982.

Kornbluth J, Spear B, Raab SS, and Wilson DB: Evidence for the role of class I and class II HLA antigens in the lytic function of a cloned line of human natural killer cells. J. Immunol. 134:728-735, 1985.

Shallal S and Kornbluth J: CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytotoxicity. Blood 96:224-233, 2000.

Fortier J and Kornbluth J: NK Lytic-Associated Molecule, involved in NK cytolytic function, is an E3 ligase. J. Immunol. 176: 6454-6463, 2006.

Hoover RG, Gullickson G, and Kornbluth J: Impaired NK cytolytic activity and enhanced tumor growth in NK Lytic-Associated Molecule (NKLAM)-deficient mice. J. Immunol. 183: 6913-69211, 2009.

Hoover RG, Gullickson G, and Kornbluth J: Natural killer lytic-associated molecule plays a role in controlling tumor dissemination and metastasis. Front. Immunol. 3 (393): 1-9, 2012. PMCID: PMC3529306

Lawrence DW, Willard PA, Cochran AM, Matchett EC, and Kornbluth J: Natural Killer Lytic-Associated Molecule (NKLAM): An E3 Ubiquitin Ligase with an Integral Role in Innate Immunity. Front. Physiol. 11:573372, 2020. PMCID: PMC7658342

Cochran AM and Kornbluth J: Extracellular vesicles from the human natural killer cell line NK3.3 have broad and potent anti-tumor activity. Front. Cell Dev. Biol. 9:698639, 2021. PMCID: PMC834358

Matchett EM and Kornbluth J: Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma. Front. Immunol. 14:1265101, 2023. PMCID: PMC10560732

McCune A and Kornbluth J: NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells. Cancers 16(1), 90, 2024. PMCID: PMC1077818